SUPERNUS PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.64M, a 15.09% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.48M, a 5.11% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.83M, a 1.97% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.51M, a 14.58% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $31.00M, a 11.69% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.75M, a 3.72% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $26.76M, a 52.32% increase from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $17.57M, a 1.91% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.64M 10-Q · filed 2026-08-03 | $17.12M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $8.48M 10-Q · filed 2026-08-03 | ||||
| 2025-12-31 | $31.00M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $7.83M 10-Q · filed 2025-11-06 | $15.33M derived: sum of 2 quarters · filed 2026-08-03 | $23.40M derived: sum of 3 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $7.51M 10-Q · filed 2026-08-03 | $15.57M derived: sum of 2 quarters · filed 2026-08-03 | |||
| 2025-03-31 | $8.07M 10-Q · filed 2026-08-03 | ||||
| 2024-12-31 | $27.75M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $7.67M 10-Q · filed 2025-11-06 | $14.23M derived: sum of 2 quarters · filed 2025-11-06 | $20.12M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $6.55M 10-Q · filed 2025-11-06 | $12.45M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $5.90M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $26.76M 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $7.92M 10-Q · filed 2024-11-04 | $14.01M derived: sum of 2 quarters · filed 2024-11-04 | $20.31M derived: sum of 3 quarters · filed 2024-11-04 | ||
| 2023-06-30 | $6.09M 10-Q · filed 2024-11-04 | $12.39M derived: sum of 2 quarters · filed 2024-11-04 | |||
| 2023-03-31 | $6.31M 10-Q · filed 2024-11-04 | ||||
| 2022-12-31 | $17.57M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $4.99M 10-Q · filed 2023-11-08 | $9.28M derived: sum of 2 quarters · filed 2023-11-08 | $13.31M derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $4.30M 10-Q · filed 2023-11-08 | $8.32M derived: sum of 2 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $4.03M 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | $17.91M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $4.03M 10-Q · filed 2022-11-09 | $9.50M derived: sum of 2 quarters · filed 2022-11-09 | $13.87M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $5.48M 10-Q · filed 2022-11-09 | $9.85M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $4.37M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $16.56M 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $4.49M 10-Q · filed 2021-11-05 | $9.45M derived: sum of 2 quarters · filed 2021-11-05 | $13.44M derived: sum of 3 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $4.96M 10-Q · filed 2021-11-05 | $8.95M derived: sum of 2 quarters · filed 2021-11-05 | |||
| 2020-03-31 | $3.99M 10-Q · filed 2021-11-05 | ||||
| 2019-12-31 | $14.85M 10-K · filed 2022-04-13 | ||||
| 2019-09-30 | $3.91M 10-Q · filed 2020-11-06 | $7.94M derived: sum of 2 quarters · filed 2020-11-06 | $11.22M derived: sum of 3 quarters · filed 2020-11-06 | ||
| 2019-06-30 | $4.02M 10-Q · filed 2020-11-06 | $7.31M derived: sum of 2 quarters · filed 2020-11-06 | |||
| 2019-03-31 | $3.29M 10-Q · filed 2020-11-06 | ||||
| 2018-12-31 | $11.29M 10-K · filed 2021-03-08 | ||||
| 2018-09-30 | $2.60M 10-Q · filed 2019-11-08 | $5.67M derived: sum of 2 quarters · filed 2019-11-08 | $8.30M derived: sum of 3 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $3.07M 10-Q · filed 2019-11-08 | $5.70M derived: sum of 2 quarters · filed 2019-11-08 | |||
| 2018-03-31 | $2.63M 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | $8.43M 10-K · filed 2020-02-28 | ||||
| 2016-12-31 | $5.93M 10-K · filed 2019-03-01 | ||||
| 2015-12-31 | $4.09M 10-K · filed 2018-03-01 | $4.23M 10-K · filed 2016-03-09 | |||
| 2014-12-31 | $2.86M 10-K · filed 2017-03-16 | $2.72M 10-K · filed 2015-03-12 | |||
| 2013-12-31 | $1.91M 10-K/A · filed 2017-01-20 | ||||
| 2012-12-31 | $443.00K 10-K · filed 2015-03-12 | ||||
| 2011-12-31 | -$82.00K 10-K · filed 2014-03-21 | ||||
| 2010-12-31 | $297.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |